- Can Iron Once a Day, Every Other Day Keep the Doctor Away?February 02, 2018 | March-April 2018, Volume 15, Issue 2
Dr. Keel looks at a study that recommends dosing of oral iron to be once every other day, rather than twice-daily, to overcome the hepcidin-mediated block of iron absorption.
- A Lot of Attention on Aplastic AnemiaJanuary 10, 2018 | January-February 2018, Volume 15, Issue 1
Dr. Keel looks at a study that reviews the use of eltrombopag in combination with antithymocyte globulin and cyclosporine in refractory severe aplastic anemia treatment-naive patients, among other studies.
- Improving Outcomes in High-Risk MDS and CMML: Which Needle(s) to Use Remain Lost in the HaystackOctober 10, 2017 | November-December 2017, Volume 14, Issue 6
Dr. Keel looks at a study that considers azacitidine-based combination chemotherapy as therapy for a subset of high-risk MDS patients with chronic myelomonocytic leukemia.
- Things Are Not Always What They Seem: Marrow Failure From a Hematopoietic Cell-Extrinsic Mechanism Due to Germline Mutations in ThrombopoietinAugust 14, 2017 | September-October 2017, Volume 14, Issue 5
Dr. Keel reviews a study that shows that patients with germline THPO mutations resulting in marrow failure do not benefit from stem cell transplantation, but instead respond to thrombopoietin mimetic therapy.
- Are We Recruiting an Army for Magneto? Optimizing Iron Utilization in HemodialysisJuly 01, 2017 | July-August 2017, Volume 14, Issue 4
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
- Precision Medicine at Work: Genetic Profiling to Guide Stem-Cell Transplantation in Myelodysplastic SyndromesMay 01, 2017 | May-June 2017, Volume 14, Issue 3
Dr. Keel reviews the use of genetic profiling to guide stem-cell transplantation in myelodysplastic syndromes.
- Where and When Did it All Go Wrong? Deciphering the Molecular Pathophysiology of Disease Progression in MDSMarch 01, 2017 | March-April 2017, Volume 14, Issue 2
Dr. Keel reviews a study that looks at how distinct molecular events affect MDS disease progression, suggesting that screening for specific mutations might be useful to predict clinical outcome.
- HIT Me With Your Best Shot: Promising Advances in HIT Prevention and TreatmentJanuary 01, 2017 | January-February 2017, Volume 14, Issue 1
Dr. Keel reviews promising advances during 2016 in HIT prevention and treatment, while mentioning the need for further trials to confirm the safety and efficacy of existing anticoagulants.
- If We Could Turn Back Time: Danazol Preserves Telomere Length in Patients With Telomere DysfunctionOctober 28, 2016 | November-December 2016, Volume 13, Issue 6
Dr. Keel discusses studies carried out to determine the efficacy of androgens to treat or prevent other disease manifestations associated with short telomere syndromes.
- CML No Longer Means Early DeathAugust 12, 2016 | September-October 2016, Volume 13, Issue 5
Dr. Keel reviews a study that looks at an increase in life expectancy for chronic myeloid leukemia (CML) patients as CML treatment has changed dramatically over time.